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Depression in the Primary Care Setting
To the Editor: In the Clinical Practice article by 
Park and Zarate (Feb. 7 issue)1 on depression in 
the primary care setting, the authors do not ad-
dress the considerable financial barriers and 
stigma that many patients with depression en-
counter with regard to accessing psychotherapy. 
We would like to call attention to a promising 
model that we are using in our practice — the 
collaborative care model — that allows us to em-
bed a behavioral health care manager into our 
usual clinical care.2
The Centers for Medicare and Medicaid Ser-
vices recently introduced billing codes for services 
provided by a behavioral health care manager 
working collaboratively with primary care pro-
viders within their own practice.3 In this model, 
patients in primary care settings are screened 
for depression with the use of a validated instru-
ment such as the Patient Health Questionnaire 9 
(PHQ-9). If the results are positive, the patients 
undergo consultation with a psychiatrist, are 
enrolled in a registry, receive a brief course of 
evidence-based psychotherapy such as cognitive 
behavioral therapy, and are monitored with the 
use of measurement-based targets. Numerous 
randomized, controlled trials have shown the 
effectiveness of this approach as compared with 
usual liaison psychiatry.4 Such innovative ap-
proaches will allow more patients to access ex-
panded mental health services within their own 
primary care practice, which is both cost-efficient 
for the patient and sustainable for the practice.
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To the Editor: As Park and Zarate discuss, non-
response to first-line antidepressants is com-
mon. The authors comment that, “Although im-
provement may be noted at as early as 2 weeks, 
full relief of symptoms may not be seen for 8 to 
12 weeks.” Unfortunately, this does little to chal-
lenge the commonly held belief that antidepres-
sants take longer than 2 weeks to take effect. In a 
meta-analysis of 47 randomized, controlled trials, 
35% of clinical improvement was seen during the 
first week and a further 25% during the second 
week.1 Furthermore, clinical improvement by 
2 weeks is a powerful predictor of subsequent 
response and remission.2 In line with a 2015 
guideline,3 we would therefore advocate reassess-
ment 2 weeks after the initiation of antidepres-
sant therapy to assess efficacy, side effects, and 
suicide risk. If there is no improvement 4 weeks 
after initiation, despite adherence to the regimen 
and an absence of coexisting substance use, it 
would be prudent to consider a medication 
change. Given that protracted depression causes 
suffering, functional decline, and even structural 
brain changes,4 clinicians may minimize this 
burden by making proactive changes to ineffec-
tive therapy.
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To the Editor: In their review article about de-
pression, Park and Zarate mention that a Lyme 
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titer should be obtained as clinically appropriate. 
It is somewhat unclear why Lyme disease was 
singled out. The vast majority of patients with 
untreated Lyme disease (at least 70%, but more 
likely closer to 90%) present with the skin lesion 
erythema migrans.1 A recent systematic study in-
volving adult patients with erythema migrans 
showed no evidence that such patients were sig-
nificantly more likely than matched healthy con-
trols to have a major depressive disorder on pre-
sentation.2 The mildly elevated Beck Depression 
Inventory–II scores at baseline strongly and di-
rectly correlated with the total number of somat-
ic symptoms and, as in another study,3 were more 
likely to be attributable to somatic symptoms 
rather than to affective depressive symptoms.
Overall, no convincing evidence has support-
ed the notion that any psychiatric illness might 
be the primary manifestation of untreated Lyme 
disease.4 If all patients with depression were 
tested for Lyme disease, thousands of misdiag-
noses would occur owing to false positive tests 
as well as background seropositivity from earlier 
resolved infections.
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To the Editor: Park and Zarate provide helpful 
guidance on antidepressant use in primary care, 
but they mention the antidepressant discontinu-
ation syndrome — sometimes considered to be a 
withdrawal syndrome — only in Table 2 of their 
article. They correctly identify the agents with a 
short half-life, paroxetine and venlafaxine, as be-
ing more likely than other antidepressants to 
provoke the discontinuation syndrome.1 How-
ever, their statement that controlled-release or 
extended-release formulations of these drugs 
“may decrease risk” of the discontinuation syn-
drome is not well supported. Extended-release 
formulations slow the rate of drug entry and re-
duce peak plasma levels but do not extend the 
elimination half-life of the drugs. Thus, sudden 
discontinuation of extended-release venlafaxine 
may provoke adverse effects in as many as 78% of 
patients within 3 days.2
Although most instances of discontinuation 
syndrome are of mild-to-moderate severity and 
last days to weeks, some cases are more severe 
and prolonged.3 Besides the avoidance of agents 
with a short half-life, discontinuation syndrome 
is probably best prevented by using a very long 
tapering schedule of 2 to 6 months, especially in 
patients who have been taking antidepressants 
for more than a year.4 Careful monitoring of the 
patient’s response to dose reduction is essential.
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The authors reply: Ellis and colleagues high-
light the role of financial barriers and stigma 
as obstacles to psychotherapy and describe the 
delivery of mental health care by means of a col-
laborative care model with an embedded behav-
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ioral health manager. We acknowledge the diffi-
culty in accessing psychotherapy, applaud their 
efforts, and strongly advocate for innovative ap-
proaches to mental health care delivery.
Moulton and Young describe a developing 
view in the field that response to first-line anti-
depressants may occur earlier than previously 
thought, and they advocate for a more aggressive 
pharmacologic approach that considers a medi-
cation switch within 4 weeks. We are sympa-
thetic to this approach but believe that it may be 
better suited to patients with urgent or refractory 
presentations than to those with mild-to-moder-
ate depression. In the meta-analysis of clinical 
trials cited by Moulton and Young,1 60% of the 
improvement was seen within the first 2 weeks, 
but a substantial amount (40%) was seen after 
this time. In addition, the final end point of the 
analysis was 6 weeks, so abatement of symp-
toms after this time was not captured. Real-
world assessments of antidepressant effects — 
such as the Sequenced Treatment Alternatives to 
Relieve Depression (STAR*D) trial2 — suggest 
that greater improvement may be seen after 
8 weeks.
Wormser and Hassett question whether Lyme 
disease should be considered as a cause of or 
contributor to depressive symptoms. We agree 
that erythema migrans is not significantly as-
sociated with depression; moreover, we are not 
suggesting that Lyme disease causes depression. 
Rather, we believe that the neuropsychiatric 
symptoms of Lyme disease (e.g., fatigue, sleep 
disturbance, and somatic depressive symptoms3) 
may manifest in a manner similar to depressive 
syndrome and thus that Lyme disease should be 
a diagnostic consideration. For the same reasons 
that Wormser and Hassett provide, we do not 
recommend screening for Lyme disease in all 
patients with depression but only when clini-
cally appropriate.
Finally, Pies contends that “controlled-release 
or extended-release formulations . . . do not 
extend the elimination half-life of the drugs.” At 
face value this seems logical. However, pharma-
cokinetic studies of venlafaxine have shown an 
overall lower maximum concentration and more 
gradual and narrower range of plasma concen-
tration changes per equivalent dose with the 
extended-release formulation than with the im-
mediate-release formulation.4 This suggests that 
missed doses or abrupt discontinuation may re-
sult in fewer side effects in the short term with 
the extended-release formulation than with the 
immediate-release formulation. Although the 
analysis by Fava and colleagues5 showed that 
78% of the patients discontinuing extended-
release venlafaxine reported adverse events, no 
events were judged to be severe, and there was 
no immediate-release comparator. Still, for either 
formulation, it seems prudent to be aware of 
discontinuation symptoms and to use a gradual 
taper.
Lawrence T. Park, M.D. 
Carlos A. Zarate, Jr., M.D.
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Teamwork in Medicine
To the Editor: In her article in the February 21 
issue,1 Rosenbaum convincingly argues that ef-
fective team collaboration is crucial in today’s 
complex health care system. One underutilized 
approach to improving clinicians’ ability to col-
laborate is to start early in their professional 
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